JPRN-jRCT2032200033
Completed
Phase 3
A Multicenter, Prospective, Randomized Controlled Trial: SMC-01: A Mobile Medical Application to Improve Self-Management of Patients with Type 2 Diabetes
Ohnishi Yukiko0 sites200 target enrollmentMay 17, 2020
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Type 2 Diabetes
- Sponsor
- Ohnishi Yukiko
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Outpatients who are 20 years of age or older at the time of obtaining consent (regardless of gender)
- •2\) Patients who have written consent at the time of Visit 1
- •3\) Patients who, at Visit 1, have been diagnosed with type 2 diabetes for at least 12 weeks (84 days)
- •4\) Patients being treated with diet and exercise therapy alone or taking hypoglycemic medications in addition to diet and exercise therapy, who have been on the same therapy for at least 12 weeks (84 days) at the time of Visit 1\.
- •5\) Patients with a Visit 1 HbA1c value of 7\.0% to 9\.0% or less
- •6\) Patients who have a smartphone device and have been using it continuously for at least 12 weeks (84 days) at the time of Visit 1\.
- •7\) Patients who have been confirmed by the investigator as having no problems with the input eligibility of the test device.
Exclusion Criteria
- •1\) Women who wish to become pregnant, are pregnant, or are breastfeeding.
- •2\) Premenopausal women with a positive pregnancy test (urine)
- •3\) Patients who have been diagnosed with type 1 diabetes
- •4\) Patients who have been diagnosed with secondary diabetes mellitus
- •5\) Patients who received insulin within 12 weeks (84 days) retroactive to Visit 1
- •6\) Patients with a history of requiring third party intervention for the treatment of hypoglycemia
- •7\) Patients with or undergoing treatment for diabetic proliferative retinopathy
- •8\) Patients who developed cardiovascular disease within 12 weeks (84 days) retroactive to Visit 1
- •9\) Patients with noncompensated heart failure
- •10\) Patients with serious hepatic impairment (ALT value (central bulk measurement at Visit 1\) greater than 3 times the upper limit of the reference value)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in unicondylar knee arthroplasty (UKA) ProcedureKCT0008693Smith & Nephew30
Not yet recruiting
Not Applicable
A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Effectiveness of the REAL INTELLIGENCE™ CORI™ in total knee arthroplasty (TKA) ProcedureDiseases of the musculoskeletal system and connective tissueKCT0008692Smith & Nephew40
Recruiting
Not Applicable
Balloon Angioplasty in Venous Anastomotic Stenoses of Hemodialysis GraftKCT0003654Soon Chun Hyang University Hospital Seoul190
Completed
Not Applicable
A Multicentre, Prospective, Randomized, Controlled, One-way Crossover Investigation of Endobronchial Valve (EBV) Therapy vs. Standard of Care (SoC) in Homogeneous EmphysemaCOPD Patients With Homogeneous EmphysemaJ44Other chronic obstructive pulmonary diseaseDRKS00006980Pulmonx International Sàrl93